First Tracks Biotherapeutics, Inc. (TRAX)
NASDAQ: TRAX · Real-Time Price · USD
45.50
+1.62 (3.69%)
At close: Aug 19, 2026, 4:00 PM EDT
45.71
+0.21 (0.46%)
After-hours: Aug 19, 2026, 7:30 PM EDT
First Tracks Biotherapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A newly independent biotech with $180 million in cash is advancing a pipeline of antibody therapies for autoimmune diseases, led by ANB033 targeting CD122. Key phase I-B trials in celiac disease and EoE are ongoing, with major data readouts expected in Q4 and mid-2027.